☆ 4.7 Letter

Risk of Misinterpretation of Ebola Virus PCR Results After rVSV ZEBOV-GP Vaccination

CLINICAL INFECTIOUS DISEASES (2015)

Journal

CLINICAL INFECTIOUS DISEASES

Volume 60, Issue 11, Pages 1725-U208

Publisher

OXFORD UNIV PRESS INC

DOI: 10.1093/cid/civ131

Keywords

-

Categories

Immunology Infectious Diseases Microbiology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Immunology

Recombinant Sudan virus and evaluation of humoral cross-reactivity between Ebola and Sudan virus glycoproteins after infection or rVSV-ΔG-ZEBOV-GP vaccination

Markus H. Kainulainen, Jessica R. Harmon, Amy N. Whitesell, Eric Bergeron, Elif Karaaslan, Caitlin M. Cossaboom, Jason H. Malenfant, Aaron Kofman, Joel M. Montgomery, Mary J. Choi, Cesar G. Albarino, Christina F. Spiropoulou

Summary: Ebola disease outbreaks are significant public health events characterized by human-to-human transmission and high mortality. These outbreaks are primarily caused by Ebola virus, but other related viruses can also induce the disease. A recent outbreak of Sudan virus in 2022 resulted in over 160 confirmed and probable cases. A study described in this report generated a recombinant Sudan virus and demonstrated its usefulness in quantifying antibody cross-reactivity between Ebola and Sudan virus glycoproteins after human infection or vaccination with an authorized Ebola virus vaccine.

EMERGING MICROBES & INFECTIONS (2023)

Add to Collection

Article Immunology

Optimal Expression, Function, and Immunogenicity of an HIV-1 Vaccine Derived from the Approved Ebola Vaccine, rVSV-ZEBOV

Hiva Azizi, Jason P. Knapp, Yue Li, Alice Berger, Marc-Alexandre Lafrance, Jannie Pedersen, Marc-Antoine de la Vega, Trina Racine, Chil-Yong Kang, Jamie F. S. Mann, Jimmy D. Dikeakos, Gary Kobinger, Eric J. Arts

Summary: The researchers used vesicular stomatitis virus (VSV) as a platform for a potential HIV-1 vaccine. However, they faced obstacles in selecting a highly immunogenic HIV-1 Envelope (Env) for maximum expression on recombinant VSV particles. By fusing the transmembrane domain (TM) and cytoplasmic tail (CT) of SIVMac239 with the HIV-1 Env, they created a novel chimera that expressed high levels on a VSV vector carrying the Ebola virus glycoprotein (GP). This new chimera, derived from a subtype A primary isolate, showed promising results in terms of antibody levels and neutralizing activity.

VACCINES (2023)

Add to Collection

Article Public, Environmental & Occupational Health

Feasibility and safety of rVSV-ZEBOV vaccination of humanitarian health workers against Ebola virus disease: an observational study

Luisa Carnino, Pauline Vetter, Nicolas Peyraud, Sigiriya Aebischer-Perone, Francois Chappuis, Angela Huttner, Laurent Kaiser, Gilles Eperon

Summary: The study aimed to assess the feasibility of vaccinating expatriate humanitarian frontline workers with rVSV-ZEBOV vaccine and report adverse events. Among 124 FLWs, most experienced at least one adverse event, but the majority of early adverse events resolved within 3 days, with fewer delayed adverse events.

JOURNAL OF TRAVEL MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo

Nicole A. Hoff, Anna Bratcher, J. Daniel Kelly, Kamy Musene, Jean Paul Kompany, Michel Kabamba, Placide Mbala-Kingebeni, Bonnie Dighero-Kemp, Gregory Kocher, Elizabeth Elliott, Cavan Reilly, Megan Halbrook, Benoit Ilunga Kebela, Adva Gadoth, Guillaume Ngoie Mwamba, Merly Tambu, David R. McIlwain, Patrick Mukadi, Lisa E. Hensley, Steve Ahuka-Mundeke, George W. Rutherford, Jean Jacques Muyembe-Tamfum, Anne W. Rimoin

Summary: This study examines the antibody response to a single-dose rVSV Delta G-ZEBOV-GP vaccination among EVD-exposed and potentially exposed populations in the DRC. The results show that the majority of vaccinated individuals developed an antibody response at 21 days and 6 months postvaccination, and the antibodies persisted over time. Women and young people had higher antibody titers.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)

Add to Collection

Article Ethics

From discovery to delivery: public sector development of the rVSV-ZEBOV Ebola vaccine

Matthew Herder, Janice E. Graham, Richard Gold

Summary: The discovery and development of the Ebola rVSV-ZEBOV vaccine demonstrate the significant role that the public sector can play in vaccine development in certain circumstances.

JOURNAL OF LAW AND THE BIOSCIENCES (2021)

Add to Collection

Article Virology

Therapeutic vaccination strategies against EBOV by rVSV-EBOV-GP: the role of innate immunity

Amanda N. Pinski, Ilhem Messaoudi

Summary: This review examines data from in vitro and in vivo studies on early immune responses to rVSV-EBOV-GP, discussing the role of innate immune activation in therapeutic protection.

CURRENT OPINION IN VIROLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial

Zacchaeus Anywaine, Houreratou Barry, Omu Anzala, Gaudensia Mutua, Sodiomon B. Sirima, Serge Eholie, Hannah Kibuuka, Christine Betard, Laura Richert, Christine Lacabaratz, M. Juliana McElrath, Stephen C. De Rosa, Kristen W. Cohen, Georgi Shukarev, Michael Katwere, Cynthia Robinson, Auguste Gaddah, Dirk Heerwegh, Viki Bockstal, Kerstin Luhn, Maarten Leyssen, Rodolphe Thiebaut, Macaya Douoguih

Summary: This study assessed the safety, tolerability, and immunogenicity of the heterologous 2-dose Ad26.ZEBOV, MVA-BN-Filo vaccination regimen in African adolescents and children. The results showed that the vaccination regimen was well tolerated with no vaccine-related serious adverse events. All vaccinees produced antibodies against the Ebola virus, with higher immune responses observed in the group with a 56-day interval between doses.

PLOS MEDICINE (2022)

Add to Collection

Article Immunology

Monitoring of Adverse Events in Recipients of the 2-Dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in the UMURINZI Ebola Vaccination Campaign

Julien Nyombayire, Rosine Ingabire, Ben Magod, Amelia Mazzei, Jean Baptiste Mazarati, Jozef Noben, Michael Katwere, Rachel Parker, Sabin Nsanzimana, Kristin M. Wall, Felix Sayinzoga, Amanda Tichacek, Cynthia Robinson, Niina Hammoud, Frances Priddy, Susan Allen, Etienne Karita

Summary: This study investigates the adverse reactions of Rwandan residents who received the Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines. The results show that febrile convulsions in young children were rare and reduced with the routine use of acetaminophen after vaccination. The vaccine regimen is generally safe and well-tolerated.

JOURNAL OF INFECTIOUS DISEASES (2023)

Add to Collection

Article Public, Environmental & Occupational Health

Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020

Mary J. Choi, Caitlin M. Cossaboom, Amy N. Whitesell, Jonathan W. Dyal, Allison Joyce, Rebecca L. Morgan, Doug Campos-Outcalt, Marissa Person, Elizabeth Ervin, Yon C. Yu, Pierre E. Rollin, Brian H. Harcourt, Robert L. Atmar, Beth P. Bell, Rita Helfand, Inger K. Damon, Sharon E. Frey

Summary: This report summarizes the recommendations for the use of the Ervebo Ebola vaccine in the United States, highlighting the contraindication for individuals with severe allergic reactions to rice protein. The vaccine is the first and only one licensed by the FDA for preventing EVD, with recommendations for preexposure vaccination for adults at highest risk.

MMWR RECOMMENDATIONS AND REPORTS (2021)

Add to Collection

Article Biochemical Research Methods

Adaptation of an rVSV Ebola vaccine purification process for rapid development of a viral vaccine candidate for SARS-CoV-2

Laura E. Kuczynski, James R. Shallow, Matthew P. Watson, Michael L. Homsy, Thomas Svab, Ashley Gruber, Richard R. Rustandi, Jianfang Hu, Michael A. Winters

Summary: This paper describes the development of purification process for a SARS-CoV-2 vaccine candidate based on the rVSV platform. Additional measures, such as the addition of endonuclease, core-shell chromatography step, and terminal sterile filtration, were needed for the SARS-CoV-2 vaccine candidate compared to the ERVEBO platform. The study demonstrates the process consistency of the vaccine candidate across four large scale batches completed within 6 months from clone selection.

BIOTECHNOLOGY JOURNAL (2023)

Add to Collection

Article Immunology

Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola

Viki Bockstal, Maarten Leyssen, Dirk Heerwegh, Bart Spiessens, Cynthia Robinson, Jeroen N. Stoop, Ramon Roozendaal, Thierry Van Effelterre, Auguste Gaddah, Griet A. Van Roey, Laura Solforosi, Roland Zahn, Benoit Callendret, Jenny Hendriks, Kerstin Luhn, Macaya Douoguih, Hanneke Schuitemaker, Johan Van Hoof

Summary: This study extrapolated the protective effect of an Ebola vaccine from animals to humans using immunologic markers and calculated the predicted survival probability. Using a logistic regression model, the vaccine's efficacy in protecting against Ebola virus was successfully inferred in humans.

NPJ VACCINES (2022)

Add to Collection

Article Public, Environmental & Occupational Health

No Evidence of rVSV-Ebola Virus Vaccine Replication or Dissemination in the Sand Fly Phlebotomus papatasi

Andrew D. Haddow, Tobin E. Rowland, Sarah L. Norris, Thomas R. Sprague, Jorge O. Lopez, Mark C. Carder, Yvonne-Marie Linton, M. Louise M. Pitt

Summary: Following feeding on an artificial blood meal containing rVSV-EBOV, laboratory-reared Phlebotomus papatasi did not show replication or dissemination of the vaccine virus in their bodies or legs at seven or 15 days post-feed. This indicates a low potential for rVSV-EBOV to replicate and disseminate in P. papatasi, a species with geographic distribution ranging from Morocco to southwest Asia and southern Europe.

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Effects of Gamma Irradiation of Human Serum Samples from rVSVδG-ZEBOV-GP (V920) Ebola Virus Vaccine Recipients on Plaque-Reduction Neutralization Assays

Rebecca J. Grant-Klein, Joseph Antonello, Rick Nichols, Sheri Dubey, Jakub Simon

Summary: Gamma irradiation can lead to approximately 20% reduction in post-vaccination neutralizing antibody titers induced by the rVSV ΔG-ZEBOV-GP vaccine (V920), without affecting pre-vaccination neutralizing antibody titers.

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2021)

Add to Collection

Article Virology

Ebola Virus GP Activates Endothelial Cells via Host Cytoskeletal Signaling Factors

Benedicte Mpia Moni, Yasuteru Sakurai, Jiro Yasuda

Summary: This study reveals that Ebola-like particles (VLPs) formed by GP, VP40, and NP activate endothelial cells (ECs) via GP, leading to apoptotic ECs disruption and dysfunction. Compared to TNF-alpha, VLPs induce overexpression of ICAM-1 at later time points. Additionally, focal adhesion kinase inhibitors were found to be potent inhibitors of TNF-alpha and VLPs-mediated ICAM-1 expression.

VIRUSES-BASEL (2022)

Add to Collection

Article Immunology

Immunogenicity of rVSVAG-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials q

Jakub K. Simon, Stephen B. Kennedy, Barbara E. Mahon, Sheri A. Dubey, Rebecca J. Grant-Klein, Ken Liu, Jonathan Hartzel, Beth-Ann G. Coller, Carolee Welebob, Mary E. Hanson, Rebecca F. Grais

Summary: This study evaluated the immune response of the ERVEBO vaccine for prevention of Ebola virus disease (EVD). The results showed that the vaccine elicited a robust and durable immune response in participants of different genders and age groups. Women and individuals with pre-existing immunity had higher immune responses.

VACCINE (2022)

Add to Collection

Article Immunology

Acute Schistosomiasis With a Schistosoma mattheei x Schistosoma haematobium Hybrid Species in a Cluster of 34 Travelers Infected in South Africa

Lieselotte Cnops, Tine Huyse, Ula Maniewski, Patrick Soentjens, Emmanuel Bottieau, Marjan Van Esbroeck, Joannes Clerinx

Summary: The diagnosis of schistosomiasis in a group of travelers with freshwater exposure in South Africa was evaluated using various diagnostic methods. Results showed that eosinophil count, Schistosoma antibody tests, and PCR assays were effective in confirming the diagnosis, with sequencing identifying a hybrid species. These findings suggest that Dral PCR can confirm the diagnosis at an earlier stage than traditional tests and may be useful in identifying hybrid species.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Review Medicine, General & Internal

Dengue: current state one year before WHO 2010-2020 goals

K. Wellekens, A. Betrains, P. De Munter, W. Peetermans

Summary: Dengue is a mosquito-borne virus infection widely spread in subtropical climates, with 40% of the world's population currently at risk. Despite the availability of a Dengue vaccine, safety and efficacy issues remain, necessitating the development of new vaccine approaches and vector-control strategies for effective prevention.

ACTA CLINICA BELGICA (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Early diagnosis and follow-up of acute schistosomiasis in a cluster of infected Belgian travellers by detection of antibodies and circulating anodic antigen (CAA): A diagnostic evaluation study

Pytsje T. Hoekstra, Marjan van Esbroeck, Claudia J. de Dood, Paul L. A. M. Corstjens, Lieselotte Cnops, Christel J. G. Van Zeijl-van der Ham, Linda J. Wammes, Govert J. van Dam, Jan Clerinx, Lisette van Lieshout

Summary: In this study, the diagnostic value of schistosome circulating anodic antigen (CAA) detection was evaluated in a cluster of 34 Belgian tourists. The UCP-LF CAA serum assay was found to be the most sensitive method for the diagnosis of early Schistosoma infections and post-treatment monitoring in travelers.

TRAVEL MEDICINE AND INFECTIOUS DISEASE (2021)

Add to Collection

Article Medicine, General & Internal

Mycobacterium avium complex and Cryptococcus neoformans co-infection in a patient with acquired immunodeficiency syndrome: a case report

Emilien Gregoire, Benoit Francois Pirotte, Filip Moerman, Antoine Altdorfer, Laura Gaspard, Eric Firre, Martial Moonen, Gilles Darcis

Summary: This case report presents a rare case of concurrent infection with Cryptococcus neoformans and Mycobacterium avium complex in an AIDS patient in the post ART era. Early detection and treatment of HIV is crucial in preventing severe OIs and their complications. Clinicians should be vigilant about the possibility of co-infections in severely immunocompromised patients.

ACTA CLINICA BELGICA (2022)

Add to Collection

Article Microbiology

Low Sensitivity of Real Time PCRs Targeting Retrotransposon Sequences for the Detection of Schistosoma japonicum Complex DNA in Human Serum

Hagen Frickmann, Ulrike Loderstadt, Beatrice Nickel, Sven Poppert, Peter Odermatt, Somphou Sayasone, Marjan Van Esbroeck, Isabel Micalessi, Lieselotte Cnops, Poom Adisakwattana, Gerard Leboulle, Olfert Landt, Thorsten Thye, Egbert Tannich

Summary: This study assessed the potential use of retrotransposon sequences from S. japonicum, S. mekongi, and S. malayensis for diagnosing Asian Schistosoma infections. While real-time PCR assays targeting S. japonicum complex showed some success, they were less effective in detecting S. mekongi DNA in human serum samples. Cross-reactions with S. mansoni or S. haematobium samples were observed, indicating the need for further evaluation of PCR assays for S. japonicum complex.

PATHOGENS (2021)

Add to Collection

Article Medicine, General & Internal

COVID-19 Antibody Detecting Rapid Diagnostic Tests Show High Cross-Reactivity When Challenged with Pre-Pandemic Malaria, Schistosomiasis and Dengue Samples

Fien Vanroye, Dorien Van den Bossche, Isabel Brosius, Bieke Tack, Marjan Van Esbroeck, Jan Jacobs

Summary: The study tested the cross-reactivity of COVID-19 Ab RDTs in detecting antibodies in pre-pandemic samples, and found certain levels of cross-reactivity in patients with malaria, schistosomiasis, and dengue. This cross-reactivity was not associated with detecting antigens, patient categories, or disease subgroups, except for two products with over 60% cross-reactivity in schistosomiasis cases.

DIAGNOSTICS (2021)

Add to Collection

Article Infectious Diseases

Plasmodium malariae after successful treatment of P. falciparum malaria with artemether-lumefantrine

Tijs K. Tournoy, Anna Rosanas-Urgell, Marjan Van Esbroeck, Emmanuel Bottieau, Ralph Huits

Summary: We reported a case of Plasmodium malariae malaria in a traveler who returned from the Democratic Republic of Congo to Belgium. This case occurred despite the individual receiving successful treatment for Plasmodium falciparum three weeks earlier and not being re-exposed to the infection in an endemic area. We discussed possible explanations for this unusual observation.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2022)

Add to Collection

Article Immunology

Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant

Kevin K. Arien, Leo Heyndrickx, Johan Michiels, Katleen Vereecken, Kurt Van Lent, Sandra Coppens, Betty Willems, Pieter Pannus, Geert A. Martens, Marjan Van Esbroeck, Maria E. Goossens, Arnaud Marchant, Koen Bartholomeeusen, Isabelle Desombere

Summary: This study reports the levels of neutralizing antibodies against Wuhan, Delta, and Omicron variants in different groups of individuals. The findings support the use of booster vaccines to prevent infection and disease caused by the Omicron variant.

NPJ VACCINES (2022)

Add to Collection

Article Medicine, General & Internal

Peritoneal tuberculosis caused by intravesical instillation with Bacillus Calmette-Guerin (BCG) following nephroureterectomy in a patient with bladder and upper tract urothelial cancer: a case report

Charlotte Allaeys, Pieter De Backer, Karel Decaestecker, Camille Berquin, Karen Decaestecker, Steven Callens, Charles Van Praet

Summary: This is a rare case of peritoneal tuberculosis in a patient after BCG instillation following bladder surgery, emphasizing the importance of being aware of possible discontinuity in the urothelium before administering BCG.

ACTA CLINICA BELGICA (2023)

Add to Collection

Article Public, Environmental & Occupational Health

Maternal and Early-Life Exposure to Antibiotics and the Risk of Autism and Attention-Deficit Hyperactivity Disorder in Childhood: a Swedish Population-Based Cohort Study

Lembris L. Njotto, Johanna Simin, Romina Fornes, Ingvild Odsbu, Isabelle Mussche, Steven Callens, Lars Engstrand, Robin Bruyndonckx, Nele Brusselaers

Summary: This study found that maternal and early-life antibiotic use is associated with an increased risk of autism and ADHD in children. The study used a large Swedish nation-wide cohort and discovered that both prenatal and early childhood antibiotic exposure are linked to a higher risk of developing these neurodevelopmental disorders. Rating: 8 out of 10.

DRUG SAFETY (2023)

Add to Collection

Review Gastroenterology & Hepatology

Intestinal helminthic infections: a narrative review to guide the hepatogastro-enterologist

M. Vanhooren, A. Stoefs, S. Van Den Broucke, M. Van Esbroeck, T. Demuyser, S. Kindt

Summary: Intestinal helminthic infections are not uncommon in Western Europe. Early recognition and management are crucial due to unspecific symptoms.

ACTA GASTRO-ENTEROLOGICA BELGICA (2023)

Add to Collection

Article Immunology

No Significant Association between 25-OH Vitamin D Status and SARS-CoV-2 Antibody Response after COVID-19 Vaccination in Nursing Home Residents and Staff

Eline Meyers, Evelien De Smet, Hanne Vercruysse, Steven Callens, Elizaveta Padalko, Stefan Heytens, Linos Vandekerckhove, Piet Cools, Wojciech Witkowski

Summary: This study investigated the association between vitamin D deficiency/supplementation and SARS-CoV-2 antibody responses after vaccination in nursing home residents and staff. The results showed that vitamin D status may not be related to a better COVID-19 vaccine antibody response, but addressing the high prevalence of vitamin D deficiency in the nursing home population remains important.

VACCINES (2023)

Add to Collection

Article Infectious Diseases

Rapid detection of S. pyogenes and S. pneumoniae in pleural fluid for diagnosis of parapneumonic empyema

Kelly De Schuyter, Jerina Boelens, Anne-Sophie Messiaen, Petra Schelstraete, Bruno Verhasselt, Diana Huis In't Veld, Steven Callens, Erica Sermijn, Yannick Vande Weygaerde, Stien Vandendriesche

Summary: This study assessed the reliability of rapid antigen detection tests for Streptococcus pyogenes and Streptococcus pneumoniae, and found that RADT can improve the accuracy of pathogen identification.

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2023)

Add to Collection

Article Infectious Diseases

A Cluster of Plasmodium ovale Infections in Belgian Military Personnel after Deployment in Kindu, Democratic Republic of Congo: A Retrospective Study

Diana Isabela Costescu Strachinaru, An Wauters, Marjan Van Esbroeck, Mihai Strachinaru, Peter Vanbrabant, Patrick Soentjens

Summary: Plasmodium ovale malaria, often neglected due to its milder course compared to Plasmodium falciparum, was identified as a hotspot among Belgian military personnel deployed in the Eastern Democratic Republic of Congo. The soldiers diagnosed with P. ovale showed long delays in both disease onset and diagnosis, and all cases were uncomplicated without relapses after treatment.

TROPICAL MEDICINE AND INFECTIOUS DISEASE (2021)

Add to Collection

Article Infectious Diseases

Infective endocarditis caused by Neisseria mucosa on a prosthetic pulmonary valve with false positive serology for Coxiella burnetii - The first described case

Antoine Altdorfer, Benoit F. Pirotte, Laura Gaspard, Emilien Gregoire, Eric Firre, Filip Moerman, Martial Moonen, Ahmed Sanoussi, Marjan Van Esbroeck, Marcella Mori

Summary: This case report describes a patient with tetralogy of Fallot who developed infective endocarditis on a prosthetic pulmonary valve caused by Neisseria mucosa. The patient underwent valve replacement surgery and a 42-day course of antibiotic treatment with a favourable outcome, despite initially being misdiagnosed with Q fever endocarditis.

IDCASES (2021)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.